<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Using a parametric <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> model, we disentangle the superimposing effects of primary and relapse therapies of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> on secondary <z:hpo ids='HP_0002664'>neoplasias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: We analyze eight randomized trials of the German Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> study group [5357 individuals, 67 secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and 97 secondary non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL)] </plain></SENT>
<SENT sid="2" pm="."><plain>Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: For <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the hazards after primary therapies are proportional (maximum at 3.4 years), while the hazard after relapse therapy is more peaked (maximum at 1.8 years) </plain></SENT>
<SENT sid="4" pm="."><plain>Intermediate and advanced stage chemotherapy resulted in a cumulative risk of 1.5%, while the risk after BEACOPP escalated is higher (4.4%, P = 0.004) and comparable with that after relapse therapy (4.5%) </plain></SENT>
<SENT sid="5" pm="."><plain>For secondary NHL, there are no differences in cumulative risk between the primary therapies (2.9%), while the risk after relapse therapy is increased (6.6%, P = 0.002) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: BEACOPP escalated moderately increases the risk of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> but not NHL </plain></SENT>
<SENT sid="7" pm="."><plain>No differences were found between other chemotherapies of advanced stages and intermediate stages </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">Secondary AML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> occurs faster after relapse treatment than after primary treatment </plain></SENT>
</text></document>